tsn

AbbVie and Umoja sign CAR-T deals worth up to $1.4B with targets towards multiple cancers

 391
0 comment
Staff at TrialSite | Quality Journalism
Jan. 7, 2024, 5:00 p.m.

AbbVie and Umoja Biopharma announced the signing of two exclusive option and license agreements to develop multiple in-situ generated CAR-T cell therapy candidates in oncology using Umoja’s proprietary VivoVec platform.

Under the initial deal, AbbVie has an exclusive option to license Umoja’s CD19-directed in-situ generated CAR-T cell therapy candidates. This includes Umoja’s UB-VV111, the lead clinical program for hematologic malignancies currently at the IND-enabling phase. 

Quality journalism costs money to produce.

Free access provides up to 10 articles

Subscription options start at $5 per month 
which is less than a Starbucks coffee!

Peter Gabriel, MD
"Publishing on TrialSite helped me secure a $20m research grant for my work."
Jona Savinda
"TrialSiteNews is my daily read for what is happening in the industry."
Lucas Van Der Hoven
"Objective, unbiased reporting on the latest news in medical research. I trust TrialSiteNews to give it to me straight."
TrialSiteNews
159 W Broadway, Suite 200
Salt Lake City, UT 84101
© 2024 - Trial Site News